Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Rocket Pharmaceuticals (RCKT) and Atreca (BCEL)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ACADIA Pharmaceuticals (ACADResearch Report), Rocket Pharmaceuticals (RCKTResearch Report) and Atreca (BCELResearch Report).

ACADIA Pharmaceuticals (ACAD)

In a report released today, Ami Fadia from Needham maintained a Hold rating on ACADIA Pharmaceuticals. The company’s shares closed last Monday at $16.62.

According to TipRanks.com, Fadia is a 3-star analyst with an average return of 3.1% and a 50.3% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Intra-Cellular Therapies, and Avadel Pharmaceuticals.

ACADIA Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $20.36, which is a 27.0% upside from current levels. In a report issued on August 1, J.P. Morgan also initiated coverage with a Hold rating on the stock with a $19.00 price target.

See the top stocks recommended by analysts >>

Rocket Pharmaceuticals (RCKT)

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Rocket Pharmaceuticals today and set a price target of $62.00. The company’s shares closed last Monday at $15.84.

According to TipRanks.com, Livshits is a 5-star analyst with an average return of 28.9% and a 44.6% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Crispr Therapeutics AG, and Taysha Gene Therapies.

Rocket Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $51.75, which is a 223.2% upside from current levels. In a report issued on July 25, Stifel Nicolaus also maintained a Buy rating on the stock with a $56.00 price target.

Atreca (BCEL)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Atreca, with a price target of $25.00. The company’s shares closed last Monday at $2.28, close to its 52-week low of $1.51.

According to TipRanks.com, Pantginis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -21.4% and a 30.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Bioline RX Ltd Sponsored ADR, Applied Genetic Technologies, and Lineage Cell Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atreca with a $17.00 average price target, implying a 553.8% upside from current levels. In a report released yesterday, Brookline Capital Markets also reiterated a Buy rating on the stock with a $17.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ACAD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos